Medicating Foster Care Children with Psychotropic Drugs: An Examination ( Childrens Issues, Laws and Programs )

Publication series :Childrens Issues, Laws and Programs

Author: Robert L. Ray;Mackenzie A. Watkins  

Publisher: Nova Science Publishers, Inc.‎

Publication year: 2016

E-ISBN: 9781619429109

P-ISBN(Paperback): 9781619428898

Subject: R985 paediatric medicine

Keyword: 暂无分类

Language: ENG

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Medicating Foster Care Children with Psychotropic Drugs: An Examination

Chapter

Higher Rates of Psychotropic Drug Prescriptions among Foster Children

Higher Rates of Potential Health Risk Indicators among Foster Children

SELECTED STATES’ PSYCHOTROPIC DRUG MONITORING PROGRAMS FALL SHORT OF AACAP- BEST PRINCIPLES GUIDELINES

CONCLUSION

RECOMMENDATION FOR EXECUTIVE ACTION

AGENCY COMMENTS AND OUR EVALUATION

APPENDIX I. OBJECTIVES, SCOPE, AND METHODOLOGY

APPENDIX II. USES AND SIDE EFFECTS OF PSYCHOTROPIC DRUGS52

APPENDIX III. LIST OF PSYCHOTROPIC DRUGS USED IN ANALYSIS

APPENDIX IV. RATES OF PSYCHOTROPIC PRESCRIPTION USAGE BY LENGTH OF TIME IN MEDICAID FEE-FOR-SERVICE

APPENDIX V. ADDITIONAL DATA ON CHILDREN WITH PRESCRIPTIONS OF AT LEAST ONE PSYCHOTROPIC DRUG

APPENDIX VI. ADDITIONAL DATA ON CONCOMITANT PRESCRIPTIONS

APPENDIX VII. ADDITIONAL DATA ON PSYCHOTROPIC DRUG PRESCRIPTIONS EXCEEDING MAXIMUM RECOMMENDED DOSES

APPENDIX VIII. ADDITIONAL DATA ON PSYCHOTROPIC PRESCRIPTIONS TO CHILDREN UNDER 1 YEAR OLD

APPENDIX IX. ADDITIONAL DATA ON PSYCHOTROPIC DRUGS WITH GAPS IN PRESCRIPTIONS OF 7 TO 29 DAYS

APPENDIX X. SELECTED STATES’ IMPLEMENTATION OF AACAP’S BEST PRINCIPLES GUIDELINES

End Notes

Chapter 2 STATEMENT OF SENATOR SCOTT BROWN. HEARING ON "THE FINANCIAL AND SOCIETAL COSTS OF MEDICATING AMERICA'S FOSTER CHILDREN"

Chapter 3 TESTIMONY OF BRYAN SAMUELS, COMMISSIONER, ADMINISTRATION ON CHILDREN, YOUTH AND FAMILIES, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. HEARING ON "THE FINANCIAL AND SOCIETAL COSTS OF MEDICATING AMERICA'S FOSTER CHILDREN"

OVERVIEW

Social-emotional, behavioral, and mental health needs of children in child welfare

Psychotropic medication use among children in foster care

DEPARTMENTAL ACTIVITIES

Future Actions

CONCLUSION

End Notes

Chapter 4 TESTIMONY OF MATT SALO, EXECUTIVE DIRECTOR, NATIONAL ASSOCIATION OF MEDICAID DIRECTORS. HEARING ON "THE FINANCIAL AND SOCIETAL COSTS OF MEDICATING AMERICA'S FOSTER CHILDREN"

MEDICAID

PHARMACEUTICAL COVERAGE FOR CHILDREN IN FOSTER CARE

CHALLENGES

SOLUTIONS

More HHS Guidance

Research on Psychotropic Impacts on Children

Integrated and Coordinated Care

Medical Policy Changes

NAMD Best Practices

Chapter 5 STATEMENT OF DR. JON MCCLELLAN, PROFESSOR, UNIVERSITY OF WASHINGTON, SEATTLE, WASHINGTON. HEARING ON "THE FINANCIAL AND SOCIETAL COSTS OF MEDICATING AMERICA'S FOSTER CHILDREN"

INDEX

The users who browse this book also browse


No browse record.